Teva, Blackstone Life Sciences Enter $400 Million Funding Deal to Advance Duvakitug

MT Newswires Live03-04

Teva Pharmaceutical Industries (TEVA) said late Tuesday that funds managed by Blackstone Life Sciences will provide $400 million over four years to support the clinical development of duvakitug.

Duvakitug is a human monoclonal antibody targeting tumor necrosis factor-like ligand 1A, or TL1A. It is currently in phase 3 clinical studies for the treatment of ulcerative colitis and Crohn's disease.

Teva is co-developing and, subject to regulatory approval, will co-commercialize duvakitug with Sanofi (SNY).

Teva said Blackstone Life Sciences will be eligible for regulatory and commercial milestone payments, as well as royalties on worldwide sales of duvakitug.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616770723?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 06:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616770723","market":"sh","top_or_hot":-1,"title":"Teva, Blackstone Life Sciences Enter $400 Million Funding Deal to Advance Duvakitug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries (TEVA) said late Tuesday that funds managed by <a href=\"https://laohu8.com/S/BX\">Blackstone</a> Life Sciences will provide $400 million over four years to support the clinical development of duvakitug.</p><p>Duvakitug is a human monoclonal antibody targeting tumor necrosis factor-like ligand 1A, or TL1A. It is currently in phase 3 clinical studies for the treatment of ulcerative colitis and Crohn's disease.</p><p>Teva is co-developing and, subject to regulatory approval, will co-commercialize duvakitug with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY).</p><p>Teva said Blackstone Life Sciences will be eligible for regulatory and commercial milestone payments, as well as royalties on worldwide sales of duvakitug.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva, Blackstone Life Sciences Enter $400 Million Funding Deal to Advance Duvakitug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva, Blackstone Life Sciences Enter $400 Million Funding Deal to Advance Duvakitug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-04 06:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries (TEVA) said late Tuesday that funds managed by <a href=\"https://laohu8.com/S/BX\">Blackstone</a> Life Sciences will provide $400 million over four years to support the clinical development of duvakitug.</p><p>Duvakitug is a human monoclonal antibody targeting tumor necrosis factor-like ligand 1A, or TL1A. It is currently in phase 3 clinical studies for the treatment of ulcerative colitis and Crohn's disease.</p><p>Teva is co-developing and, subject to regulatory approval, will co-commercialize duvakitug with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY).</p><p>Teva said Blackstone Life Sciences will be eligible for regulatory and commercial milestone payments, as well as royalties on worldwide sales of duvakitug.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616770723","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616770723","pubTimestamp":1772577181,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries (TEVA) said late Tuesday that funds managed by Blackstone Life Sciences will provide $400 million over four years to support the clinical development of duvakitug.Duvaki","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","BK4007":"制药","SNY":"赛诺菲安万特","BK4596":"哈里斯概念","BK4566":"资本集团","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4584":"避孕概念","BK4557":"大麻股","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4588":"碎股","TEVA":"梯瓦制药","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"Teva与Blackstone Life Sciences达成4亿美元融资协议以推进Duvakitug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1,"TEVA":1},"content_text":"Teva Pharmaceutical Industries (TEVA) said late Tuesday that funds managed by Blackstone Life Sciences will provide $400 million over four years to support the clinical development of duvakitug.Duvakitug is a human monoclonal antibody targeting tumor necrosis factor-like ligand 1A, or TL1A. It is currently in phase 3 clinical studies for the treatment of ulcerative colitis and Crohn's disease.Teva is co-developing and, subject to regulatory approval, will co-commercialize duvakitug with Sanofi (SNY).Teva said Blackstone Life Sciences will be eligible for regulatory and commercial milestone payments, as well as royalties on worldwide sales of duvakitug.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616770723","isCrawlerRequest":true}